Open access
Oncological Outcomes and Safety Profiles of Adjuvant Nivolumab in Muscle‐Invasive Urothelial Carcinoma
Satoshi Katayama
Tatsushi Kawada
K. Mori
K. Iwatani
Shota Inoue
Tomofumi Watanabe
Ichiro Tsuboi
T. Yamanoi
T. Iwata
Kazuma Tsuboi
Wataru Murao
Tetsuya Nakada
K. Ogawa
A. Matsukawa
T. Yanagisawa
S. Nishimura
K. Bekku
K. Wada
Takahiro Kimura
M. Araki
Medicine
Abstract
Perioperative immunotherapy has become the standard of care in patients with high‐risk muscle‐invasive urothelial carcinoma (MIUC). This study aimed to clarify oncological outcomes and safety profiles of adjuvant nivolumab therapy in MIUC, focusing on upper tract urothelial carcinoma (UTUC).